Luciana Basili Dias Candidíase vulvovaginal em pacientes gestantes

Referências Bibliográficas 88
Bates S. Vaginal discharge. Curr. Obstet. Gynaecol. 2003; 13: 218-23.
Bauters TGM, Dhont MA, Temmerman MIL, Nelis HJ. Prevalence of vulvovaginal candidíases
and susceptibility to fluconazole in women. Am J Obstet Gynecol. 2002; 187: 569-74.
Biasoli MS, Tosello ME, Bottai H, Cuesta C, Magaró HM. Efecto de la temperatura y el pH em
la adherencia de Candida albicans in vitro. Rev. Iberoam Micol. 1999; 16: 46-9.
BidartH T. Rol de voriconazol y caspofungina en terapia antifungica. Rev. Chil. Infectol. 2004;
21: 13-9.
Bossche HV, Marichal P. Azole antifungals: mode of action. In: Yamaguchi H, Kobaiashi GS,
Takahashi H, editores. Recent Progress in Antifungal Chemotherapy. New York: Marcel Dekker,
INC; 1992. p. 25-40.
Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of
mechanisms of action. Antimicrob. Agents Chemother. 1990; 34: 183-8.
Campbell MC, Stewart JL. Identification of individual fungal isolates. In: The Medical
Mycology Handbook. Nee York: John Wiley & Sons; 1980. p. 210-348.
Candido RC, Toloi MRT, Franceschini SA, Garcia FR, Minto ECM. In vitro activity of
antimycotic agents determined by E-test method against vaginal Candida species.
Mycopathologia. 1999; 144: 15-20.
Carrillo Munõz AJ, Quindós G, Cárdenes GD, Vargas RA, Arévalo P, Brió S, et al. Evalución
del médio Chromalbicans Agar para la identificación presuntiva de Candida albicans. Rev.
Iberoam Micol. 2001; 18: 501-8.
Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines.
Morbidity and Mortality Weekly Report. 2002; 51:1-77.